GlassScriptPhysician profile
Monica A Thomas
NPI 1124661954
$2,007.83
in general payments reported to CMS, 2019-2025
29 companies · $936 in 2025
The $936 reported for 2025 was more than what 94% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.13 · 2023: $53.75 · 2024: $959 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.70 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $660.65 | 2024-2025 | Rexulti, Nuedexta |
| Amgen INC. | $175.00 | 2025 | Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.18 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $80.29 | 2024 | Yupelri |
| Novo Nordisk INC | $79.93 | 2024-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $76.47 | 2022-2023 | Xarelto |
| Axsome Therapeutics, INC. | $67.75 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $57.39 | 2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $56.51 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $55.33 | 2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $50.56 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $49.89 | 2024-2025 | |
| Esperion Therapeutics, INC. | $44.45 | 2024-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $43.97 | 2024-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.99 | 2024 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.69 | 2024 | |
| Xeris Pharmaceuticals, INC. | $42.43 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.90 | 2023-2024 | Jardiance |
| Averitas Pharma INC. | $24.21 | 2024 | Qutenza |
| Corium, LLC | $21.80 | 2023 | Azstarys |
| Lundbeck LLC | $21.60 | 2024 | Rexulti |
| Viatris Specialty LLC | $21.43 | 2025 | Yupelri |
| Scilex Pharmaceuticals INC. | $20.84 | 2025 | |
| Noven Therapeutics, LLC | $20.42 | 2024 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $20.14 | 2025 | Austedo Xr |
| Ardelyx, INC. | $19.63 | 2025 | Ibsrela |
| Collegium Pharmaceutical, INC. | $19.43 | 2025 | Jornay Pm |
| Abbott Laboratories | $16.93 | 2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $14.02 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.